Edwards Lifesciences Corporation, a prominent company in the medical device sector, has been experiencing a turbulent few years. While it has experienced periods of substantial growth, including a boost in Q1 2025 revenues and earnings per share (EPS) beating expectations, it has also faced several challenges. This includes a class-action lawsuit against the firm and its stocks underperforming the Dow, Nasdaq, and S&P 500. Despite this, the company has achieved significant milestones, including receiving FDA approval for the Edward's Shapien 3 and 8-year data confirming the durability of Edwards' RESILIA tissue. The company has completed the sale of its Critical Care business and has also made strategic acquisitions of JenaValve and Endotronix. The company's outlook appears to be brightening with Piper Sandler upgrading its stock and raising its target price. The company's commitment to innovating in structural heart technology is significant and contributes positively to its growth strategy.
Edwards Lifesciences Corp EW News Analytics from Mon, 15 Jul 2024 07:00:00 GMT to Tue, 24 Jun 2025 13:15:20 GMT - Rating 5 - Innovation 7 - Information 5 - Rumor -3
